Personalized CRISPR therapies, gene-editing treatments built around one patient's specific mutation rather than a disease shared by millions, just lost one of their early backers. Aurora Therapeutics has scrapped its lead program and laid off staff, seven months after the company launched. A spokesperson declined to say how many people were let go or whether any of its three-person leadership team would remain with the company.

What Aurora was building

CRISPR is a molecular tool that can locate and rewrite specific sequences in a patient's DNA. Standard drug development targets conditions shared by large patient populations; the personalized approach sets a different goal: build a separate therapy for each individual, shaped around their exact mutation. Aurora launched with the aim of scaling that process, turning a technically demanding, case-by-case effort into something repeatable. The company's chief scientific officer left earlier this year, before the lead program was formally abandoned.

How a bigger competitor shifted the picture

Aurora appears to have been undercut by Beam Therapeutics, a larger and more established company in gene editing. The timing was notable. One month after Aurora launched, Beam announced it was already advancing its own set of custom gene editors for the exact same disease Aurora had selected as its lead target. That left a seven-month-old startup competing with a more established company on the same disease, in the same category of therapy, with no meaningful head start separating them.

What the company disclosed

A spokesperson declined to say how many employees were laid off. The spokesperson also declined to confirm whether any member of the three-person leadership team would stay on. The chief scientific officer's departure earlier this year preceded the formal shutdown of the lead program.

Related reading